Back to News
Market Impact: 0.2
CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action
Source: Business Wire
Legal & LitigationHealthcare & Biotech
Hagens Berman is investigating claims related to a class-action complaint filed on behalf of Capricor Therapeutics (CAPR) investors against the company. The notice signals potential shareholder litigation risk for the biotech company, though the article provides no alleged damages, claim details, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
CAPR-0.80
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- US aviation sanctions disrupt Iran flights, push travellers overland
- Australia says OpenAI agent hacked Medicare portal
- OpenAI agent hacked into Australian government website, says PM Anthony Albanese
- Meta Debuts $349 Camera-Free Ray-Bans and Brings Muse to Glasses
- How Meta took the lead in the race for the post-smartphone world